Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adobe Systems Inc (ADBE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Adobe Systems Inc
Recursion Pharmaceuticals Inc

Price performance

Price movement over the last 24 hours

Key statistics

Adobe Systems Inc vs Recursion Pharmaceuticals Inc — how do they compare? Adobe Systems Inc trades at $220.51 (market cap $88.06B), while Recursion Pharmaceuticals Inc trades at $3.71 (market cap $2.04B). The key difference: Adobe Systems Inc is far larger — about 43.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

ADBERXRX
Market Cap
$88.06B$2.04B
Volume
5,187,646
Sector
TechnologyHealth
52-Week High
$382.24$6.79
52-Week Low
$193.41$2.84
Enterprise Value
$89.50B$1.46B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adobe Systems Inc

Adobe (ADBE) trades at $220.35, up 1.05% with a bullish technical signal. The company reported strong Q1 2026 earnings of $5.96 EPS, beating estimates, and maintains robust profitability with 89.4% gross margins. Revenue growth accelerated to $23.77B in 2025, while valuation ratios remain attractive with P/E at 12.67. Recent institutional buying activity contrasts with some analyst concerns about AI competition.

Adobe presents a compelling investment case with strong fundamentals and growth trajectory, though AI disruption risks and recent stock volatility warrant caution. The consensus price target of $246.75 suggests 12% upside potential, supported by consistent earnings beats and expanding cash flows.

Recursion Pharmaceuticals Inc

RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).

Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adobe Systems Inc

Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.

Read more on ADBE

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX